World of DTC Marketing
AUGUST 30, 2022
Digital ad spending in the industry will reach $15.84 billion in 2022. Although growth in digital budgets is slowing, we estimate the category will see nearly $20 billion in spending in 2024. For every $1 million invested in online banner ads, just 0.1%, or $1,000, derives value for brands, resulting in $999,000 wasted by brands. So why is pharma wasting so much money?
Medical Device Success
AUGUST 28, 2022
Reading time: 2 – 4 minutes. I am honored to have two event planning experts, Lauren Dustman, Senior Manager, Global Events at Hyperfine and Kimberly Stanséll, Meeting, Trade Show and Event Strategy Consultant to guide us today in this conversation. Combined, these ladies manage about 100 shows and events annually. Today’s episode is the first of two episodes about medical trade shows.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
AUGUST 29, 2022
Rural health systems should be the champions of virtual care delivery, according to Jim Weinstein, Microsoft’s senior vice president of health equity and innovation. He and Sheri Dodd, vice president and general manager of Medtronic Care Management Services, laid out recommendations for rural providers to establish scalable and sustainable virtual care programs during a conference held last week by Sanford Health.
Integrity Solutions
SEPTEMBER 2, 2022
One of the first big workforce catchphrases to go viral after the onset of the pandemic was “The Great Resignation,” as employees began to reevaluate their careers and leave their jobs in record numbers. This max exodus of talent may be slowing down a bit, but it’s far from over. More than two years later, even with the threat of a recession looming in the background, companies continue to struggle with finding talent to fill open positions.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
World of DTC Marketing
AUGUST 29, 2022
DTC marketers spend a lot of time and money gaining insights into patients and caregivers. That information should be shared with HCPs and insurers to understand better the barriers and opportunities of treating patients. A sales representative for a biotech company shared information with oncologists about patients’ attitudes towards treatment options, including the company’s brand.
pharmaphorum
AUGUST 31, 2022
Kaiku Health’s year-old alliance with Novartis to develop a digital patient monitoring and management (DPPM) system for patients with melanoma is being extended, according to the two partners. The original agreement last year focused on melanoma patients who are receiving BRAF/MEK combination therapies – specifically Novartis’ Tafinlar (dabrafenib) and Mekinist (trametinib) drugs – and has resulted in the development of a digital module tailored to their needs.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmaceutical Technology
SEPTEMBER 2, 2022
Novo Nordisk has signed a definitive agreement for the acquisition of clinical-stage biopharmaceutical firm Forma Therapeutics for $20 for each share in cash or a total equity price of $1.1bn. Forma focuses on researching, developing and marketing new therapies for patients with sickle cell disease (SCD), rare hematologic diseases and cancers. Through the acquisition, Novo Nordisk plans to boost its presence in sickle cell disease and rare blood disorders.
World of DTC Marketing
AUGUST 31, 2022
According to STAT News, “Americans born in 2021 can expect to live for just 76.1 years — the lowest life expectancy has been since 1996, according to a new government analysis published Wednesday. This is the biggest two-year decline — 2.7 years in total — in almost 100 years.” It’s only going to get worse too. The Covid-19 pandemic is the primary cause of the decline, but we are ignoring another statistic.
PM360
AUGUST 29, 2022
In the pharmaceutical business, as with any other business, you can’t market what you haven’t brought to market. It’s no secret that few (if any) other industries face the scientific, economic, and regulatory hurdles in bringing products to the people as this one does. The hurdles are there for good reason, of course. The U.S. Food and Drug Administration (FDA) and their international peers protect us all from ineffective, substandard, and even dangerous compounds, whether produced willfully by
MedCity News
SEPTEMBER 2, 2022
A new Stanford study revealed that among Medicaid patients who had never taken an opioid, 30% developed an opioid dependency following their first prescription. The research showed that opioids that have historically marketed as “safe,” such as tramadol, actually carry quite a high addiction risk for vulnerable populations.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
PharmaVoice
AUGUST 30, 2022
The Community Alliance Network is the latest industry initiative looking to the pharmacy counter to help improve trial recruitment diversity.
European Pharmaceutical Review
AUGUST 30, 2022
Researchers from UPV/EHU-University of the Basque Country, Spain, have successfully produced different types of starch-based pharmaceutical tablets using 3D printing. The aim of the study, published in the International Journal of Pharmaceutics , was to produce 3D printed starch-based tablets for the tailored delivery of hydrophobic drugs. Hydrophobic drugs – those that poorly water soluble – account for some 40% of marketed drugs and the 60% of the drug candidates in research, the paper notes.
PharmaTech
AUGUST 28, 2022
In a new podcast titled, “DeltaV™ Spectral Process Analytical Technology (PAT): Achieve Real-Time, Closed-Loop PAT in Manufacturing,” find out how embedding PAT directly into the control system enables life sciences manufacturers to take a simplified approach to achieving real-time manufacturing, compliance with confidence, greater ROI and delivery of quality treatments to market faster.
MedCity News
SEPTEMBER 2, 2022
Medable recently launched a software solution to shorten the launch times for decentralized vaccine trials. The company says the software can reduce trial deployment timelines from more than 12 weeks on average to as short as five weeks.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
PharmaVoice
AUGUST 29, 2022
A collaboration between Stanford University researchers and Komodo Health aims to advance knowledge of lingering COVID symptoms, health disparities and intervention strategies.
PM360
AUGUST 29, 2022
Members of Generation Z are emerging into adulthood and quickly becoming one of the most discerning, thoughtful cohorts of consumers in U.S. history. As they grow more financially independent, they will begin to use their large collective spending power to choose healthcare options that fit their lifestyle, ethics, and personal brand. In a previous post , I talked about how to tailor healthcare messaging to this technologically minded, brand-conscious, and convenience-seeking generation.
Pharmaceutical Technology
AUGUST 28, 2022
Moderna has f iled patent infringement lawsuits in the US District Court for the District of Massachusetts and the Regional Court of Düsseldorf in Germany against Pfizer and BioNTech over messenger ribonucleic acid (mRNA) technology. Pfizer and BioNTech’s Covid-19 vaccine, Comirnaty, is said to have infringed patents filed by Moderna between 2010 and 2016 for its mRNA technology.
MedCity News
AUGUST 30, 2022
Health data company CuriMeta launched on Tuesday and announced the close of a $6 million seed funding round led by its two institutional partners, BJC HealthCare and the Washington University School of Medicine. The company’s mission is to leverage its two institutional partners’ deep data resources to create more useful data that enables quicker discoveries of new diagnostics and medical interventions.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
PharmaVoice
AUGUST 29, 2022
Rachel Meyers, chief scientific officer at Faze Medicines, is helping guide the company towards the development of biomolecular condensates — an emerging field that could transform drug discovery.
PM360
AUGUST 29, 2022
Recently, industry and community patient advocacy pioneers came together for the Chief Patient Officer Summit. Though the title is rare, having a leader highly placed within a biopharmaceutical company solely responsible for integrating patient perspectives is no longer Pollyanna. In the context of the dueling, incongruous dynamics of patient empowerment, cost-sharing, and indisputable disparities, it’s strategic, ethical, and intuitive.
pharmaphorum
SEPTEMBER 1, 2022
Cyrus Massoumi, founder of Dr. B, tells us about his online platform that makes physician assessment readily available to patients and provides access to COVID-19 therapeutics that may otherwise be difficult to obtain. COVID-19 antiviral medications Paxlovid (nirmatrelvir/ritonavir) and Lagevrio (molnupiravir) must be taken within five days of the onset of symptoms, but obtaining these medications within that window is difficult for some.
MedCity News
AUGUST 30, 2022
In a recent interview, Jennifer Cubino, COO of BC Platforms, discussed regulatory differences between the U.S., the European Union and other countries amid ongoing efforts to encourage patients who want to share their data.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
PharmaVoice
SEPTEMBER 1, 2022
A long-time analyst, Tycho Peterson brings his business savvy to the C-suite at Adaptive, where he began as CFO in June with a knowledge of what works and what doesn't in the diagnostics space.
PM360
AUGUST 29, 2022
Over-the-Counter (OTC) and Prescription (Rx) brands have invested over $3 billion in linear TV advertising during the first half of 2022, with no signs of letting up. Amidst a fragmented Convergent TV landscape that offers consumers a multitude of ways to watch their preferred programming, linear TV is still a valuable environment for pharma advertisers.
pharmaphorum
AUGUST 30, 2022
Neurocrine Biosciences has featured on lists of potential takeover candidates for years, but has now taken the lead on a buyout of UK biotech Diurnal that if consummated will extend its therapeutic focus further into hormonal disorders. The 27.5 pence-a-share cash deal values Diurnal at around £48.3 million ($57 million), a 144% premium to the biotech’s closing share price on Friday.
MedCity News
AUGUST 29, 2022
Community pharmacies need to ramp up now to be ready for 2023 and ensure their operations, technology and partnerships are in tip-top shape should more unexpected economic turbulence arrive.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
European Pharmaceutical Review
AUGUST 29, 2022
What are the clients’ goals in seeking out a personalised culture media solution? Oftentimes, our clients’ goals are to increase cell growth, improve protein titers and optimise product quality attributes. Biopharmaceutical manufacturers find that custom media can provide tailored solutions. What are some of the challenges manufacturers face? Discussion often exposes significant problems with lot-to-lot consistency with current media suppliers and scale-up to supply all their manufacturing sites
PM360
AUGUST 29, 2022
The adoption of Electronic Health Records (EHRs) had been a slow process until 2009 when federal incentives to healthcare professionals (HCPs) to switch from paper to EHR charts became available, and when HCPs were rewarded via higher payments for meeting meaningful use criteria. HCPs needed to show they could utilize a certified EHR in a meaningful way (i.e., make patient’s health information available online within a short period of time, facilitate the electronic exchange of health informatio
pharmaphorum
AUGUST 30, 2022
Bayer is pressing ahead with a phase 3 trial of its oral Factor XIa inhibitor asundexian, a new anticoagulant, despite missing efficacy targets in two mid-stage studies. The OCEANIC trial programme will investigate the potential of asundexian in up to 30,000 patients with atrial fibrillation (AF) as well as patients with a non-cardioembolic ischaemic stroke or high-risk transient ischemic attack (TIA), said Bayer.
MedCity News
AUGUST 30, 2022
The four companies are Alma, Headway, NOCD and Ophelia. Alma and Headway will help Empire expand its mental health provider network, while NOCD and Ophelia will address specific conditions: obsessive-compulsive disorder and opioid use disorder, respectively.
Advertiser: ZoomInfo
In times of economic uncertainty, account-based strategies are essential. According to several business analysts and practitioners, ABM is a necessity for creating more predictable revenue. Research shows that nearly three-quarters of marketers (74%) already have the resources needed to build successful ABM programs.
Expert insights. Personalized for you.
270 
Let's personalize your content